YLHM
CMMB

Yelin Lapidot Holdings Management’s Chemomab Therapeutics CMMB Stock Holding History

Yelin Lapidot Holdings Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-144,573
Closed -$671K – 92
2025
Q2 		$671K Hold
144,573
– – 0.12% 66
2025
Q1 		$630K Sell
144,573
-41,459
-22% -$291K 0.12% 67
2024
Q4 		$1.35M Sell
186,032
-16,397
-8% -$104K 0.23% 56
2024
Q3 		$1.27M Buy
+202,429
New +$1.14M 0.21% 56

Other funds holding CMMB

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Yelin Lapidot Holdings Management's CMMB Position: Q3 2025 in Review

Yelin Lapidot Holdings Management sold out of Chemomab Therapeutics (CMMB) in Q3 2025, closing a stake of 144,573 shares — an estimated $671K sold.

Yelin Lapidot Holdings Management first reported a position in CMMB in Q3 2024 and held it in 4 quarters. The position peaked at $1.35M in Q4 2024. 10 funds tracked by Wall St. Rank hold CMMB as of Q3 2025.

  • Yelin Lapidot Holdings Management reported no remaining Chemomab Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Yelin Lapidot Holdings Management sold 144,573 Chemomab Therapeutics shares in Q3 2025, an estimated $671K.
  • Yelin Lapidot Holdings Management first reported a position in Chemomab Therapeutics in Q3 2024 and held it in 4 quarters.
  • Yelin Lapidot Holdings Management's Chemomab Therapeutics position peaked at $1.35M in Q4 2024.
  • 10 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2025.

Based on Yelin Lapidot Holdings Management's 13F filing for Q3 2025, filed 27 Oct 2025.